Myriad Genetics, Inc. Partners With PharmaMar S.A. for New HRD Test

Myriad Genetics, Inc. ( MYGN ) on Tuesday revealed that it signed an agreement with PharmaMar, a marine-derived drug developer to test its homologous recombination deficiency or HRD test on patients who were part of PharmaMar's Phase II clinical study of PM1183, the company's drug candidate. Peter Meldrum, President and Chief Executive of Myriad Genetics stated, "We believe HRD status is an effective mechanism for assessing patient response to DNA-damaging drugs and look forward to working closely with PharmaMar on this new companion diagnostic program."